Hoang Bao Tram Tran
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Hoang Bao Tram Tran has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Huu Dat Nguyen
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
2 shared publications - Thanh Trung Nguyen
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
2 shared publications - Young Eun Kim
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
2 shared publications - Dong Gyun Ko
Department of Physiology, College of Medicine, Hallym University, Chuncheon 24252, Korea
1 shared publication Hye Joung Choi
Department of Neurology Hallym University Sacred Heart Hospital, Hallym University Anyang Republic of Korea
1 shared publication- Hye Joung Choi
Department of Neurology, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang-si, Republic of Korea
1 shared publication
Latest Publications
- 21 September 2026
- Published by Wiley in Movement Disorders
Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study
Background: α ‐Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α ‐synuclein seeds can be detected by real‐time quaking‐induced conversion (RT‐QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large‐scale applications. We therefore evaluated the feasibility of detecting pathogenic α ‐synuclein using urine‐derived neuronal extracellular vesicles (NEVs). Methods: Urine‐derived NEVs were enriched by direct immunoprecipitation using L1CAM‐conjugated magnetic beads. The RT‐QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). Results: Urine‐derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine‐based RT‐QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC ( P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC ( P < 0.05 in all). Conclusions: We developed and optimized a completely non‐invasive urine‐derived NEV α ‐synuclein RT‐QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.
- 21 September 2026
- Published by Wiley in Movement Disorders
Urine‐Derived Neuronal Extracellular Vesicle α ‐Synuclein Seed Amplification Assay for Synucleinopathies: A Non‐Invasive Biomarker Study
Background: α ‐Synuclein aggregation is a pathological hallmark of synucleinopathies, including Parkinson's disease (PD) and multiple system atrophy (MSA). Although pathogenic α ‐synuclein seeds can be detected by real‐time quaking‐induced conversion (RT‐QuIC), current assays primarily rely on cerebrospinal fluid, whose invasiveness limits repeated and large‐scale applications. We therefore evaluated the feasibility of detecting pathogenic α ‐synuclein using urine‐derived neuronal extracellular vesicles (NEVs). Methods: Urine‐derived NEVs were enriched by direct immunoprecipitation using L1CAM‐conjugated magnetic beads. The RT‐QuIC assay was performed in 26 patients with PD, 13 with MSA, and 25 disease controls, including 16 healthy controls (HC), 4 with progressive supranuclear palsy (PSP), and 5 with normal pressure hydrocephalus (NPH). Results: Urine‐derived NEVs exhibited characteristic neuronal and exosomal markers and a typical extracellular vesicle size distribution. The urine‐based RT‐QuIC assay distinguished PD from disease controls with 73.1% sensitivity and 84% specificity, and MSA from disease controls with 76.9% sensitivity and 84% specificity. When compared with HC alone, sensitivity and specificity were 73.1% and 93.8% for PD, and 76.9% and 93.8% for MSA, respectively. Kinetic analysis showed higher maximum fluorescence intensity and area under the curve (AUC) in PD compared with both disease controls and HC ( P < 0.001 in all). MSA also demonstrated higher maximum fluorescence intensity than HC and increased AUC compared with both disease controls and HC ( P < 0.05 in all). Conclusions: We developed and optimized a completely non‐invasive urine‐derived NEV α ‐synuclein RT‐QuIC assay that demonstrates high specificity and moderate sensitivity for synucleinopathies. This approach warrants further validation in larger cohorts. © 2026 International Parkinson and Movement Disorder Society.
- 11 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1383
TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells
- 11 August 2026
- Published by Springer Nature in Molecular Biology Reports
- Vol. 53 (1) , 1383
TP53 status is associated with differential stress-marker expression and APP maturation in colon cancer cells